Language
Denmark

Supply shortage · 04.09.2026

Supply shortage Denmark: Pinex 1000 mg suppositorier

Affected country: Denmark · Reported period: Anfang Mai – Early October 2026 · Active ingredient: Paracetamol

CountryDenmark
PZNnicht angegeben
ENRLMS-ID 3897f706-dcbf-4816-b0a2-0c6633206c80
Notification typeSupply shortage
StartAnfang Mai
Expected endEarly October 2026
Last update04.09.2026
ReasonSupply difficulties
ATCN02BE01
Hospital-relevantNo

Notice context

A supply shortage has been recorded for Pinex 1000 mg suppositorier in Denmark. The stated reason is “Supply difficulties”. The notice concerns the active ingredient Paracetamol and is not identified as hospital-relevant.

This information describes the reported supply status and is not medical or pharmaceutical treatment advice. Availability, alternatives and further measures must be assessed for each individual case by the responsible pharmaceutical market participants.

Primary source: Lægemiddelstyrelsen

Official shortage notice for Denmark. Responsibility and update procedures follow the information supplied by the relevant authority.

Check the official notice list →

Implications for procurement and the supply chain

The notice for Pinex 1000 mg suppositorier is a supply signal concerning Paracetamol in Denmark. The published reason “Supply difficulties” determines which data should be verified first.

For delivery or distribution issues, handover points, transport routes, temperature control, customs status, recipient authorisation and confirmed lead times should be checked.

Decision route for this supply case

  1. Confirm the notice, product identity, period and actual demand with the primary source and accountable market participants.
  2. Assess handover points, alternative routes, temperature, customs and recipient status, and confirmed lead times.
  3. Document release, stock status, GDP evidence, warehousing and transport process, and escalation responsibility.

Inter-Pharma can structure the B2B case, potential sourcing and warehousing routes, and operational implementation. Clinical decisions, regulatory permissibility, product release and actual availability remain with the accountable parties.

Request a structured supply review →

Operational shortage resilience: GDP warehousing and pharmaceutical storage

For distribution disruption, defined stock for Pinex 1000 mg suppositorier in Cheb can support confirmed alternative routes to Denmark.

Inter-Pharma combines GDP-oriented pharmaceutical storage in Czechia with batch and expiry control, FEFO, stock status, picking and dispatch preparation in its own Cheb operation.

Storage at 15–25 °C or any 2–8 °C requirement is derived solely from the product specification and confirmed for the project.

Operational checks for this notice

  • Match product identity using record LMS-ID 3897f706-dcbf-4816-b0a2-0c6633206c80, active ingredient, strength, dosage form and pack.
  • Confirm the reported status and the period Anfang Mai to Anfang Oktober 2026 with the primary source and potential suppliers.
  • Document demand, stock coverage, open orders and lawful alternative or sourcing routes for the specific case.
  • Clarify temperature, batch, expiry, stock status, recipient authorisation and GDP evidence before cross-border supply.

Relevant services and specialist pages

The following B2B topics are particularly relevant when handling a shortage involving Pinex 1000 mg suppositorier:

Related topics